Latest News

Latest News

2017 CLLSA Cambridge members Conference Dr Follows video available

The meeting was opened by David Innes as chairman of the CLLSA. This was followed by a presentation by Dr Follows talking about CLL - The disease and its treatment in 2017 and beyond. The afternoon session started with facilitated small group discussions. An opportunity to share tips for coping with CLL and was then followed by three stories from individuals affected by CLL.

 

AbbVie launches first ever series of mindfulness podcasts to support people living with blood cancers

PRESS RELEASE

AbbVie launches first ever series of mindfulness podcasts to support people living with blood cancers

 

  • In collaboration with AbbVie, mindfulness expert Dr Caroline Hoffman has developed a series of new podcast audio recordings specifically tailored to help support people living with blood cancers, and their partners or carers

2016 CLLSA Glasgow Members Meeting

There were 4 medical presentations: two given by
Dr Alison McCraig Affiliate (Paul O'Gorman Leukaemia Research Centre) Glasgow University

as well as presentations by

Dr Emilio Cosimo Research Associate (Paul O'Gorman Leukaemia Research Centre) Glasgow University
Dr Ailsa Holroyd Clinical Research Fellow (Institute of Cancer Sciences) Glasgow University.

The presentations can be found here

European Medical Agency - Rixathon

European Medical Agency - On 21 April 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Rixathon, intended for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukaemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA).

NICE says YES to Ibrutinib to treat England and Wales NHS CLL patients

CLLSA are extremely pleased by the NICE decision to approve Ibrutinib to treat NHS England and Wales chronic lymphocytic leukaemia patients.

Today’s Final Appraisal Determination (FAD) recommends that:

1.1Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults:

· who have had at least 1 prior therapy or